ARQT - FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years | Benzinga
On Tuesday, the FDA approved Arcutis Biotherapeutics Inc’s (NASDAQ:ARQT) supplemental new drug application (sNDA) for Zoryve (roflumilast) cream, 0.15%, for mild to moderate atopic dermatitis in patients six years of age and older.
“Today marks the third FDA approval of a commercial product for Arcutis in just the last two years, and we are thrilled to be able to offer ZORYVE cream 0.15% as a new steroid-free treatment option to children and adults living with AD,” said Frank Watanabe, president and CEO of Arcutis.
Arcutis intends to make Zoryve cream 0.15% widely available via key wholesaler and dermatology pharmacy channels as a new treatment option by the end of July.
In ...